CSF2 and breast carcinoma: Although several Phase III trials, such as nelipepimut-S with GM-CSF in breast cancer, did not show substantial increases in survival outcomes, these findings highlight the complexities of tumour immunology rather than the ineffectiveness of peptide vaccines themselves (70).